Posts in Antibody Discussion Forum

*Antibody Technology Interest Network Presentation:*



*Rapid Discovery of Functional Antibodies for SARS-CoV-2*





The COVID-19 pandemic highlights the importance of a flexible and rapid
response to real-time development of medical countermeasures for
life-threatening viral pathogens. Using human B cells from survivors are a
potential source of therapeutic antibodies, Dr. Carnahan will describe the
pandemic response platform developed and deployed at the Vanderbilt Vaccine
Center that has led to a large panel of anti-viral antibodies directed at
SARS-CoV-2, including several antibodies currently in advanced clinical
development.

*Monday, October 26, 2020 11:00 a.m.–12:00 p.m. ET *Register here
<https://us02web.zoom.us/meeting/register/tZEscOiorTsvHNwYx2ZgZi_I9SH5l_OAD8Fj>

Register today to join us for this timely and informative presentation.



Speakers:



*Robert Carnahan, Ph.D.*
<https://www.vumc.org/crowe-lab/person/robert-carnahan-phd>
Associate Director, Vanderbilt Vaccine Center

Associate Professor, Pediatrics and Radiology and Radiologic Sciences

Vanderbilt University Medical Center



*David Blum, Ph.D.* <https://www.bmb.uga.edu/directory/people/david-blum>

Director, Bioexpression and Fermentation Facility

Director, Master of Biomanufacturing and Bioprocessing

University of Georgia

*[image: A screenshot of a cell phone Description automatically generated]*




*Monoclonal Antibodies from Bench to Bedside: Development in an Academic
Laboratory Core. Challenges*




*Monday, August 24, 2020 11:00 a.m.–12:00 p.m. ET **Add to Calendar
<https://us02web.zoom.us/meeting/tZYoduihqDwqHd3R3FpdHkIUCBBxdSejoq2R/ics>*

*Register Here
<https://us02web.zoom.us/j/82511967079?pwd=SUo5WG1rWG9aNGd4ZHUrQWQ0WDhTdz09>*

This presentation will address different approaches that successfully
develop an anti-immune checkpoint antibody and other antibodies licensed to
Pharma companies and in ongoing clinical trials. Other approaches under
development will also be addressed.



Register today to join us for this timely and informative presentation.



Speakers:



*David Blum, Ph.D.*

Director, Bioexpression and Fermentation Facility

Director, Master of Biomanufacturing and Bioprocessing

University of Georgia



*Laura Bover, PhD*

Professor

Depts. of Genomic Medicine/Immunology

Director, Monoclonal Antibodies Core Facility

MD Anderson Cancer Center
University of Texas

Yep
Once I hear from Ed.

Frances

ZRC 1563
Office     646-888-2354
Mobile   516-967-0656


On 7/30/20, 9:38 AM, "Antibody Discussion Forum on behalf of Bover,Laura"
<email obscured> on behalf of <email obscured>> wrote:

    Yes, please propose several times or later I send you my available ! Great!

    Laura Bover, PhD
    Professor
    Director Monoclonal Antibody Core Facility
    University of Texas M.D.Anderson Cancer Center
    Associate member of The University of Texas Graduate School of Biomedical
Sciences at Houston
    Member of the Scientific Review Committee 2 (former CRC 2)
    Member of the Steering Committee of the Immunology Program GSBS
    Immunology Department/ Genomics Medicine Department
    7455 Fannin St<x-apple-data-detectors://1/1> Room 1SCR4.2021
    Houston- TX 77054<x-apple-data-detectors://2/0>
    T  713-563-3301<tel:713-563-3301>
    F 713-563-3276<tel:713-563-3276>
    <email obscured><email obscured>>

    On Jul 30, 2020, at 7:53 AM, <email obscured>" <email obscured>>
wrote:

    WARNING: This email originated from outside of MD Anderson. Please validate
the sender's email address before clicking on links or attachments as they may
not be safe.

    Ed and Laura

        Can we set up a time learn about subtractive immunization early next
week?
        In the mean time I’ll or the cyclophosphamide.

    ARG Discussion Forum Members,

        Does anyone else want to attend?

    Frances


    Frances Weis-Garcia, Ph.D.

    Head
    Bi-Institutional Antibody and Bioresource Core Facility

    Associate Laboratory Member
    Immunology Program

    Memorial Sloan Kettering Cancer Center
    1275 York Avenue, New York, NY 10065
    T 646.888.2354   C 516.967.0656

    ABCF-MSKCC
website<https://urldefense.com/v3/__https://www.mskcc.org/research-advantage/core-facilities/monoclonal-antibody-core-facility__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQavGbEqZ$
>

    Adjunct Faculty
    Center for Clinical and Translational Science

    The Rockefeller University
    1230 York Avenue, New York, NY 10065
    T 212.327.7030

    ABCF-RU
website<https://urldefense.com/v3/__https://www.rockefeller.edu/monoclonal/__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQStlvFdx$
>


    Please note that this e-mail and any files transmitted with it may be
privileged, confidential, and protected from disclosure under applicable law.
If the reader of this message is not the intended recipient, or an employee or
agent responsible for delivering this message to the intended recipient, you
are hereby notified that any reading, dissemination, distribution, copying, or
other use of this communication or any of its attachments is strictly
prohibited.  If you have received this communication in error, please notify
the sender immediately by replying to this message and deleting this message,
any attachments, and all copies and backups from your computer.


    =====================================================================

        Please note that this e-mail and any files transmitted from
        Memorial Sloan Kettering Cancer Center may be privileged, confidential,
        and protected from disclosure under applicable law. If the reader of
        this message is not the intended recipient, or an employee or agent
        responsible for delivering this message to the intended recipient,
        you are hereby notified that any reading, dissemination, distribution,
        copying, or other use of this communication or any of its attachments
        is strictly prohibited.  If you have received this communication in
        error, please notify the sender immediately by replying to this message
        and deleting this message, any attachments, and all copies and backups
        from your computer.

    ――
    View topic
https://urldefense.com/v3/__http://list.abrf.org/r/topic/UGk03QWN9LUZhf49lemWo__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQUrtoCZq$
    Leave group <email obscured>?Subject=Unsubscribe

    The information contained in this e-mail message may be privileged,
confidential, and/or protected from disclosure. This e-mail message may contain
protected health information (PHI); dissemination of PHI should comply with
applicable federal and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review,
disclosure, use, dissemination, distribution, or copying of this message or any
attachment (or the information contained therein) is strictly prohibited. If
you think that you have received this e-mail message in error, please notify
the sender by return e-mail and delete all references to it and its contents
from your systems.

    ――
    View topic http://list.abrf.org/r/topic/2Ah9zjtxUijOERBGsq2mML
    Leave group <email obscured>?Subject=Unsubscribe




    *** Only open attachments or links from trusted senders. Report phishing to
<email obscured> ***

=====================================================================

     Please note that this e-mail and any files transmitted from
     Memorial Sloan Kettering Cancer Center may be privileged, confidential,
     and protected from disclosure under applicable law. If the reader of
     this message is not the intended recipient, or an employee or agent
     responsible for delivering this message to the intended recipient,
     you are hereby notified that any reading, dissemination, distribution,
     copying, or other use of this communication or any of its attachments
     is strictly prohibited.  If you have received this communication in
     error, please notify the sender immediately by replying to this message
     and deleting this message, any attachments, and all copies and backups
     from your computer.

Absolutely.

Frances

ZRC 1563
Office     646-888-2354
Mobile   516-967-0656


On 7/30/20, 10:18 AM, "Antibody Discussion Forum on behalf of Angel Sampson"
<email obscured> on behalf of <email obscured>> wrote:

    Dear all,

    Is it possible for me to join the Zoom call to learn more about subtractive
immunization. I have been wanting to try it here at UF.

    Kind regards,

    Angel

    Edith “Angel” Sampson, Ph.D.
    Monoclonal Antibody Scientific Director

    UF ICBR
    2033 Mowry Road, Gainesville, FL 32610
    Biotech.ufl.edu | Tel: 352.273.8039| Fax: 352.273.8070



    -----Original Message-----
    From: Antibody Discussion Forum <email obscured>> On Behalf Of
Bover,Laura
    Sent: Thursday, July 30, 2020 9:38 AM
    To: <email obscured>
    Subject: Re: [ABRF Ab Forum] [EXT] Subtractive Immunization

    [External Email]

    Yes, please propose several times or later I send you my available ! Great!

    Laura Bover, PhD
    Professor
    Director Monoclonal Antibody Core Facility University of Texas M.D.Anderson
Cancer Center Associate member of The University of Texas Graduate School of
Biomedical Sciences at Houston Member of the Scientific Review Committee 2
(former CRC 2) Member of the Steering Committee of the Immunology Program GSBS
Immunology Department/ Genomics Medicine Department
    7455 Fannin St<x-apple-data-detectors://1/1> Room 1SCR4.2021
    Houston- TX 77054<x-apple-data-detectors://2/0>
    T  713-563-3301<tel:713-563-3301>
    F 713-563-3276<tel:713-563-3276>
    <email obscured><email obscured>>

    On Jul 30, 2020, at 7:53 AM, <email obscured>" <email obscured>>
wrote:

    WARNING: This email originated from outside of MD Anderson. Please validate
the sender's email address before clicking on links or attachments as they may
not be safe.

    Ed and Laura

        Can we set up a time learn about subtractive immunization early next
week?
        In the mean time I’ll or the cyclophosphamide.

    ARG Discussion Forum Members,

        Does anyone else want to attend?

    Frances


    Frances Weis-Garcia, Ph.D.

    Head
    Bi-Institutional Antibody and Bioresource Core Facility

    Associate Laboratory Member
    Immunology Program

    Memorial Sloan Kettering Cancer Center
    1275 York Avenue, New York, NY 10065
    T 646.888.2354   C 516.967.0656

    ABCF-MSKCC
website<https://urldefense.com/v3/__https://www.mskcc.org/research-advantage/core-facilities/monoclonal-antibody-core-facility__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQavGbEqZ$
>

    Adjunct Faculty
    Center for Clinical and Translational Science

    The Rockefeller University
    1230 York Avenue, New York, NY 10065
    T 212.327.7030

    ABCF-RU
website<https://urldefense.com/v3/__https://www.rockefeller.edu/monoclonal/__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQStlvFdx$
>


    Please note that this e-mail and any files transmitted with it may be
privileged, confidential, and protected from disclosure under applicable law.
If the reader of this message is not the intended recipient, or an employee or
agent responsible for delivering this message to the intended recipient, you
are hereby notified that any reading, dissemination, distribution, copying, or
other use of this communication or any of its attachments is strictly
prohibited.  If you have received this communication in error, please notify
the sender immediately by replying to this message and deleting this message,
any attachments, and all copies and backups from your computer.


    =====================================================================

        Please note that this e-mail and any files transmitted from
        Memorial Sloan Kettering Cancer Center may be privileged, confidential,
        and protected from disclosure under applicable law. If the reader of
        this message is not the intended recipient, or an employee or agent
        responsible for delivering this message to the intended recipient,
        you are hereby notified that any reading, dissemination, distribution,
        copying, or other use of this communication or any of its attachments
        is strictly prohibited.  If you have received this communication in
        error, please notify the sender immediately by replying to this message
        and deleting this message, any attachments, and all copies and backups
        from your computer.

    ――
    View topic
https://urldefense.com/v3/__http://list.abrf.org/r/topic/UGk03QWN9LUZhf49lemWo__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQUrtoCZq$
    Leave group <email obscured>?Subject=Unsubscribe

    The information contained in this e-mail message may be privileged,
confidential, and/or protected from disclosure. This e-mail message may contain
protected health information (PHI); dissemination of PHI should comply with
applicable federal and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review,
disclosure, use, dissemination, distribution, or copying of this message or any
attachment (or the information contained therein) is strictly prohibited. If
you think that you have received this e-mail message in error, please notify
the sender by return e-mail and delete all references to it and its contents
from your systems.

    ――
    View topic
https://urldefense.proofpoint.com/v2/url?u=http-3A__list.abrf.org_r_topic_2Ah9zjtxUijOERBGsq2mML&d=DwIFaQ&c=sJ6xIWYx-zLMB3EPkvcnVg&r=F6AO--4VYeLfDWXyalUQRQ&m=4iz1voPUApsW7XoXCeDbHEh3oVdv-G37GcJDCaOxbeA&s=hhSVRO1MsAk0UvQzbLnmFWUuZ96ZXVu_Rv1ybRTQqnM&e=
    Leave group <email obscured>?Subject=Unsubscribe


    ――
    View topic http://list.abrf.org/r/topic/5z9iGvqarHaHnBHHdaCRhs
    Leave group <email obscured>?Subject=Unsubscribe




    *** Only open attachments or links from trusted senders. Report phishing to
<email obscured> ***

=====================================================================

     Please note that this e-mail and any files transmitted from
     Memorial Sloan Kettering Cancer Center may be privileged, confidential,
     and protected from disclosure under applicable law. If the reader of
     this message is not the intended recipient, or an employee or agent
     responsible for delivering this message to the intended recipient,
     you are hereby notified that any reading, dissemination, distribution,
     copying, or other use of this communication or any of its attachments
     is strictly prohibited.  If you have received this communication in
     error, please notify the sender immediately by replying to this message
     and deleting this message, any attachments, and all copies and backups
     from your computer.

Yes, please propose several times or later I send you my available ! Great!

Laura Bover, PhD
Professor
Director Monoclonal Antibody Core Facility
University of Texas M.D.Anderson Cancer Center
Associate member of The University of Texas Graduate School of Biomedical
Sciences at Houston
Member of the Scientific Review Committee 2 (former CRC 2)
Member of the Steering Committee of the Immunology Program GSBS
Immunology Department/ Genomics Medicine Department
7455 Fannin St<x-apple-data-detectors://1/1> Room 1SCR4.2021
Houston- TX 77054<x-apple-data-detectors://2/0>
T  713-563-3301<tel:713-563-3301>
F 713-563-3276<tel:713-563-3276>
<email obscured><email obscured>>

On Jul 30, 2020, at 7:53 AM, <email obscured>" <email obscured>> wrote:

WARNING: This email originated from outside of MD Anderson. Please validate
the sender's email address before clicking on links or attachments as they may
not be safe.

Ed and Laura

    Can we set up a time learn about subtractive immunization early next week?
    In the mean time I’ll or the cyclophosphamide.

ARG Discussion Forum Members,

    Does anyone else want to attend?

Frances


Frances Weis-Garcia, Ph.D.

Head
Bi-Institutional Antibody and Bioresource Core Facility

Associate Laboratory Member
Immunology Program

Memorial Sloan Kettering Cancer Center
1275 York Avenue, New York, NY 10065
T 646.888.2354   C 516.967.0656

ABCF-MSKCC
website<https://urldefense.com/v3/__https://www.mskcc.org/research-advantage/core-facilities/monoclonal-antibody-core-facility__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQavGbEqZ$
>

Adjunct Faculty
Center for Clinical and Translational Science

The Rockefeller University
1230 York Avenue, New York, NY 10065
T 212.327.7030

ABCF-RU
website<https://urldefense.com/v3/__https://www.rockefeller.edu/monoclonal/__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQStlvFdx$
>


Please note that this e-mail and any files transmitted with it may be
privileged, confidential, and protected from disclosure under applicable law.
If the reader of this message is not the intended recipient, or an employee or
agent responsible for delivering this message to the intended recipient, you
are hereby notified that any reading, dissemination, distribution, copying, or
other use of this communication or any of its attachments is strictly
prohibited.  If you have received this communication in error, please notify
the sender immediately by replying to this message and deleting this message,
any attachments, and all copies and backups from your computer.

=====================================================================

    Please note that this e-mail and any files transmitted from
    Memorial Sloan Kettering Cancer Center may be privileged, confidential,
    and protected from disclosure under applicable law. If the reader of
    this message is not the intended recipient, or an employee or agent
    responsible for delivering this message to the intended recipient,
    you are hereby notified that any reading, dissemination, distribution,
    copying, or other use of this communication or any of its attachments
    is strictly prohibited.  If you have received this communication in
    error, please notify the sender immediately by replying to this message
    and deleting this message, any attachments, and all copies and backups
    from your computer.

――
View topic
https://urldefense.com/v3/__http://list.abrf.org/r/topic/UGk03QWN9LUZhf49lemWo__;!!PfbeBCCAmug!wVUFEDGZknG4iLngHzB3DVUQXfsU6doiBiI0jvvegef4wgmYdnvM0bvZQUrtoCZq$
Leave group <email obscured>?Subject=Unsubscribe

The information contained in this e-mail message may be privileged,
confidential, and/or protected from disclosure. This e-mail message may contain
protected health information (PHI); dissemination of PHI should comply with
applicable federal and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review,
disclosure, use, dissemination, distribution, or copying of this message or any
attachment (or the information contained therein) is strictly prohibited. If
you think that you have received this e-mail message in error, please notify
the sender by return e-mail and delete all references to it and its contents
from your systems.

Ed and Laura

     Can we set up a time learn about subtractive immunization early next week?
     In the mean time I’ll or the cyclophosphamide.

ARG Discussion Forum Members,

     Does anyone else want to attend?

Frances


Frances Weis-Garcia, Ph.D.

Head
Bi-Institutional Antibody and Bioresource Core Facility

Associate Laboratory Member
Immunology Program

Memorial Sloan Kettering Cancer Center
1275 York Avenue, New York, NY 10065
T 646.888.2354   C 516.967.0656

ABCF-MSKCC
website<https://www.mskcc.org/research-advantage/core-facilities/monoclonal-antibody-core-facility>

Adjunct Faculty
Center for Clinical and Translational Science

The Rockefeller University
1230 York Avenue, New York, NY 10065
T 212.327.7030

ABCF-RU website<https://www.rockefeller.edu/monoclonal/>


Please note that this e-mail and any files transmitted with it may be
privileged, confidential, and protected from disclosure under applicable law.
If the reader of this message is not the intended recipient, or an employee or
agent responsible for delivering this message to the intended recipient, you
are hereby notified that any reading, dissemination, distribution, copying, or
other use of this communication or any of its attachments is strictly
prohibited.  If you have received this communication in error, please notify
the sender immediately by replying to this message and deleting this message,
any attachments, and all copies and backups from your computer.

=====================================================================

     Please note that this e-mail and any files transmitted from
     Memorial Sloan Kettering Cancer Center may be privileged, confidential,
     and protected from disclosure under applicable law. If the reader of
     this message is not the intended recipient, or an employee or agent
     responsible for delivering this message to the intended recipient,
     you are hereby notified that any reading, dissemination, distribution,
     copying, or other use of this communication or any of its attachments
     is strictly prohibited.  If you have received this communication in
     error, please notify the sender immediately by replying to this message
     and deleting this message, any attachments, and all copies and backups
     from your computer.

Hi all,
Has anyone employed the mRNA vaccine technologies to make mAbs?  If so, do you
have a protocol?
Best,

Scott

________________________________

Email Disclaimer: www.stjude.org/emaildisclaimer
Consultation Disclaimer: www.stjude.org/consultationdisclaimer

Thanks Laura.

If the investigator is game, and he should be since there is no cost to him,
I'll arrange zoom call with the 3 of us.

Frances

ZRC 1563
Office     646-888-2354
Mobile   516-967-0656


On 7/17/20, 3:18 PM, "Antibody Discussion Forum on behalf of Bover,Laura"
<email obscured> on behalf of <email obscured>> wrote:

    Hi Frances, agree with Edward.
    I would use separate mice. In our experience with Phospho-peptides was kind
of easy and we injected only the phospho and screen against both. Also during
immunization if you use peptide KLH, if we don't see responses during serum
titration, the last boosts we inject only the peptide no KLH.

    Subtractive immunization, we did only once using cells expressing the
unknown target in one footpad and the cells target negative in the other,
collecting only LN from the footpad with positive cells injection. Very
successful (2 clones that actually identified the target) but we had a reporter
cell system to identify antibodies that block a pathway. And cells were Human.
     I would be interested in having access to that protocol Ed, if possible.
Sometimes, we have similar projects but with peptides.

    Thanks!!
    Laura


    On 7/17/20, 10:47 AM, "Antibody Discussion Forum on behalf of
<email obscured>" <email obscured> on behalf of <email obscured>>
wrote:


        Will do. Need to talk to PI next Wed and if he is ok with me doing this
for free as proof of principle in my hands we'll set up a zoom meeting.

        Stay well.

        Frances

        ZRC 1563
        Office     646-888-2354
        Mobile   516-967-0656


        On 7/17/20, 11:23 AM, "Antibody Discussion Forum on behalf of
Greenfield, Edward A.,Ph.D." <email obscured> on behalf of
<email obscured>> wrote:

            Let me know if you want to go over the protocol.   There are a few
nuances that can make a big difference.

            Ed.

            -----Original Message-----
            From: Antibody Discussion Forum <email obscured>> On Behalf
Of <email obscured>
            Sent: Friday, July 17, 2020 11:18 AM
            To: <email obscured>
            Subject: Re: [ABRF Ab Forum] Re: Help ... before I make a mistake

                    External Email - Use Caution

            As always, thanks Ed.  I really value your input.

            Have yet to do subtractive immunizations, but this seems to be the
perfect project to try it on.

            This point mutation is C to a Y, so I am anticipating it not be too
hard to get something that binds the mutant but the WT maybe a problem since we
do not know what the C is likely crosslinked with/to.

            Frances

            ZRC 1563
            Office     646-888-2354
            Mobile   516-967-0656


            On 7/17/20, 10:47 AM, "Antibody Discussion Forum on behalf of
Greenfield, Edward A.,Ph.D." <email obscured> on behalf of
<email obscured>> wrote:

                Hi Frances -

                I would immunize the wt peptide separately from the mutant,
especially since it is only a point mutation.  I would also use subtractive
immunization to reduce the number of cross-reactive B and T cells for both the
wt and mutant peptides.  Does the point mutation induce a conformational or
charge change?  If so, it will increase your chances to get specific
antibodies.

                Best,
                Ed.

                -----Original Message-----
                From: Antibody Discussion Forum <email obscured>> On
Behalf Of Frances Weis-Garcia
                Sent: Friday, July 17, 2020 10:39 AM
                To: <email obscured>
                Subject: [ABRF Ab Forum] Help ... before I make a mistake

                        External Email - Use Caution

                I want to make sequence specific antibodies - some that bind WT
and others that bind the point mutation.

                I was going to put both peptide sequences into the same group
of mice (WT and Point Mutation) ... but than I wondered if that would bias the
response to ones that that do NOT discriminate ... so I should put them into
different mice ...

                Thoughts???
                ――
                View topic
https://urldefense.com/v3/__http://list.abrf.org/r/topic/7ugNCrtB0ER0xjmzyoP9R3__;!!PfbeBCCAmug!xm3lLejiK-YNm9wK1nrSF5V3fhakBkCqD05Tdvf5WlRrKtOQbhflijOlb5K5YXIb$
                Leave group <email obscured>?Subject=Unsubscribe



                The information in this e-mail is intended only for the person
to whom it is
                addressed. If you believe this e-mail was sent to you in error
and the e-mail
                contains patient information, please contact the Partners
Compliance HelpLine at
https://urldefense.com/v3/__http://www.partners.org/complianceline__;!!PfbeBCCAmug!xm3lLejiK-YNm9wK1nrSF5V3fhakBkCqD05Tdvf5WlRrKtOQbhflijOlbwSvZi4F$
. If the e-mail was sent to you in error
                but does not contain patient information, please contact the
sender and properly
                dispose of the e-mail.

                ――
                View topic
https://urldefense.com/v3/__http://list.abrf.org/r/topic/7I7kxNfiFRin61wAX6OXqm__;!!PfbeBCCAmug!xm3lLejiK-YNm9wK1nrSF5V3fhakBkCqD05Tdvf5WlRrKtOQbhflijOlbxXIJQnr$
                Leave group <email obscured>?Subject=Unsubscribe




                *** Only open attachments or links from trusted senders. Report
phishing to <email obscured> ***

=====================================================================

                 Please note that this e-mail and any files transmitted from
                 Memorial Sloan Kettering Cancer Center may be privileged,
confidential,
                 and protected from disclosure under applicable law. If the
reader of
                 this message is not the intended recipient, or an employee or
agent
                 responsible for delivering this message to the intended
recipient,
                 you are hereby notified that any reading, dissemination,
distribution,
                 copying, or other use of this communication or any of its
attachments
                 is strictly prohibited.  If you have received this
communication in
                 error, please notify the sender immediately by replying to
this message
                 and deleting this message, any attachments, and all copies and
backups
                 from your computer.

            ――
            View topic
https://urldefense.com/v3/__http://list.abrf.org/r/topic/4gLhmUZHtfinZkX0nIyQC__;!!PfbeBCCAmug!xm3lLejiK-YNm9wK1nrSF5V3fhakBkCqD05Tdvf5WlRrKtOQbhflijOlbwDpiHq8$
            Leave group <email obscured>?Subject=Unsubscribe


            ――
            View topic
https://urldefense.com/v3/__http://list.abrf.org/r/topic/7ckBVTDUFz5zZAGuePiy90__;!!PfbeBCCAmug!xm3lLejiK-YNm9wK1nrSF5V3fhakBkCqD05Tdvf5WlRrKtOQbhflijOlb3ASnsT6$
            Leave group <email obscured>?Subject=Unsubscribe




        =====================================================================

             Please note that this e-mail and any files transmitted from
             Memorial Sloan Kettering Cancer Center may be privileged,
confidential,
             and protected from disclosure under applicable law. If the reader
of
             this message is not the intended recipient, or an employee or
agent
             responsible for delivering this message to the intended recipient,
             you are hereby notified that any reading, dissemination,
distribution,
             copying, or other use of this communication or any of its
attachments
             is strictly prohibited.  If you have received this communication
in
             error, please notify the sender immediately by replying to this
message
             and deleting this message, any attachments, and all copies and
backups
             from your computer.

        ――
        View topic
https://urldefense.com/v3/__http://list.abrf.org/r/topic/4TGVoJyy3jZP82BvUMx1UL__;!!PfbeBCCAmug!xm3lLejiK-YNm9wK1nrSF5V3fhakBkCqD05Tdvf5WlRrKtOQbhflijOlb7I9GGpx$
        Leave group <email obscured>?Subject=Unsubscribe




    The information contained in this e-mail message may be privileged,
confidential, and/or protected from disclosure. This e-mail message may contain
protected health information (PHI); dissemination of PHI should comply with
applicable federal and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review,
disclosure, use, dissemination, distribution, or copying of this message or any
attachment (or the information contained therein) is strictly prohibited. If
you think that you have received this e-mail message in error, please notify
the sender by return e-mail and delete all references to it and its contents
from your systems.

    ――
    View topic http://list.abrf.org/r/topic/3H7W42tnUnMwWrTkeUTQwz
    Leave group <email obscured>?Subject=Unsubscribe




=====================================================================

     Please note that this e-mail and any files transmitted from
     Memorial Sloan Kettering Cancer Center may be privileged, confidential,
     and protected from disclosure under applicable law. If the reader of
     this message is not the intended recipient, or an employee or agent
     responsible for delivering this message to the intended recipient,
     you are hereby notified that any reading, dissemination, distribution,
     copying, or other use of this communication or any of its attachments
     is strictly prohibited.  If you have received this communication in
     error, please notify the sender immediately by replying to this message
     and deleting this message, any attachments, and all copies and backups
     from your computer.

Will do. Need to talk to PI next Wed and if he is ok with me doing this for
free as proof of principle in my hands we'll set up a zoom meeting.

Stay well.

Frances

ZRC 1563
Office     646-888-2354
Mobile   516-967-0656


On 7/17/20, 11:23 AM, "Antibody Discussion Forum on behalf of Greenfield,
Edward A.,Ph.D." <email obscured> on behalf of
<email obscured>> wrote:

    Let me know if you want to go over the protocol.   There are a few nuances
that can make a big difference.

    Ed.

    -----Original Message-----
    From: Antibody Discussion Forum <email obscured>> On Behalf Of
<email obscured>
    Sent: Friday, July 17, 2020 11:18 AM
    To: <email obscured>
    Subject: Re: [ABRF Ab Forum] Re: Help ... before I make a mistake

            External Email - Use Caution

    As always, thanks Ed.  I really value your input.

    Have yet to do subtractive immunizations, but this seems to be the perfect
project to try it on.

    This point mutation is C to a Y, so I am anticipating it not be too hard to
get something that binds the mutant but the WT maybe a problem since we do not
know what the C is likely crosslinked with/to.

    Frances

    ZRC 1563
    Office     646-888-2354
    Mobile   516-967-0656


    On 7/17/20, 10:47 AM, "Antibody Discussion Forum on behalf of Greenfield,
Edward A.,Ph.D." <email obscured> on behalf of
<email obscured>> wrote:

        Hi Frances -

        I would immunize the wt peptide separately from the mutant, especially
since it is only a point mutation.  I would also use subtractive immunization
to reduce the number of cross-reactive B and T cells for both the wt and mutant
peptides.  Does the point mutation induce a conformational or charge change?
If so, it will increase your chances to get specific antibodies.

        Best,
        Ed.

        -----Original Message-----
        From: Antibody Discussion Forum <email obscured>> On Behalf Of
Frances Weis-Garcia
        Sent: Friday, July 17, 2020 10:39 AM
        To: <email obscured>
        Subject: [ABRF Ab Forum] Help ... before I make a mistake

                External Email - Use Caution

        I want to make sequence specific antibodies - some that bind WT and
others that bind the point mutation.

        I was going to put both peptide sequences into the same group of mice
(WT and Point Mutation) ... but than I wondered if that would bias the response
to ones that that do NOT discriminate ... so I should put them into different
mice ...

        Thoughts???
        ――
        View topic http://list.abrf.org/r/topic/7ugNCrtB0ER0xjmzyoP9R3
        Leave group <email obscured>?Subject=Unsubscribe



        The information in this e-mail is intended only for the person to whom
it is
        addressed. If you believe this e-mail was sent to you in error and the
e-mail
        contains patient information, please contact the Partners Compliance
HelpLine at
        http://www.partners.org/complianceline . If the e-mail was sent to you
in error
        but does not contain patient information, please contact the sender and
properly
        dispose of the e-mail.

        ――
        View topic http://list.abrf.org/r/topic/7I7kxNfiFRin61wAX6OXqm
        Leave group <email obscured>?Subject=Unsubscribe




        *** Only open attachments or links from trusted senders. Report
phishing to <email obscured> ***



    =====================================================================

         Please note that this e-mail and any files transmitted from
         Memorial Sloan Kettering Cancer Center may be privileged,
confidential,
         and protected from disclosure under applicable law. If the reader of
         this message is not the intended recipient, or an employee or agent
         responsible for delivering this message to the intended recipient,
         you are hereby notified that any reading, dissemination, distribution,
         copying, or other use of this communication or any of its attachments
         is strictly prohibited.  If you have received this communication in
         error, please notify the sender immediately by replying to this
message
         and deleting this message, any attachments, and all copies and backups
         from your computer.

    ――
    View topic http://list.abrf.org/r/topic/4gLhmUZHtfinZkX0nIyQC
    Leave group <email obscured>?Subject=Unsubscribe


    ――
    View topic http://list.abrf.org/r/topic/7ckBVTDUFz5zZAGuePiy90
    Leave group <email obscured>?Subject=Unsubscribe

=====================================================================

     Please note that this e-mail and any files transmitted from
     Memorial Sloan Kettering Cancer Center may be privileged, confidential,
     and protected from disclosure under applicable law. If the reader of
     this message is not the intended recipient, or an employee or agent
     responsible for delivering this message to the intended recipient,
     you are hereby notified that any reading, dissemination, distribution,
     copying, or other use of this communication or any of its attachments
     is strictly prohibited.  If you have received this communication in
     error, please notify the sender immediately by replying to this message
     and deleting this message, any attachments, and all copies and backups
     from your computer.

As always, thanks Ed.  I really value your input.

Have yet to do subtractive immunizations, but this seems to be the perfect
project to try it on.

This point mutation is C to a Y, so I am anticipating it not be too hard to get
something that binds the mutant but the WT maybe a problem since we do not know
what the C is likely crosslinked with/to.

Frances

ZRC 1563
Office     646-888-2354
Mobile   516-967-0656


On 7/17/20, 10:47 AM, "Antibody Discussion Forum on behalf of Greenfield,
Edward A.,Ph.D." <email obscured> on behalf of
<email obscured>> wrote:

    Hi Frances -

    I would immunize the wt peptide separately from the mutant, especially
since it is only a point mutation.  I would also use subtractive immunization
to reduce the number of cross-reactive B and T cells for both the wt and mutant
peptides.  Does the point mutation induce a conformational or charge change?
If so, it will increase your chances to get specific antibodies.

    Best,
    Ed.

    -----Original Message-----
    From: Antibody Discussion Forum <email obscured>> On Behalf Of
Frances Weis-Garcia
    Sent: Friday, July 17, 2020 10:39 AM
    To: <email obscured>
    Subject: [ABRF Ab Forum] Help ... before I make a mistake

            External Email - Use Caution

    I want to make sequence specific antibodies - some that bind WT and others
that bind the point mutation.

    I was going to put both peptide sequences into the same group of mice (WT
and Point Mutation) ... but than I wondered if that would bias the response to
ones that that do NOT discriminate ... so I should put them into different mice
...

    Thoughts???
    ――
    View topic http://list.abrf.org/r/topic/7ugNCrtB0ER0xjmzyoP9R3
    Leave group <email obscured>?Subject=Unsubscribe



    The information in this e-mail is intended only for the person to whom it
is
    addressed. If you believe this e-mail was sent to you in error and the
e-mail
    contains patient information, please contact the Partners Compliance
HelpLine at
    http://www.partners.org/complianceline . If the e-mail was sent to you in
error
    but does not contain patient information, please contact the sender and
properly
    dispose of the e-mail.

    ――
    View topic http://list.abrf.org/r/topic/7I7kxNfiFRin61wAX6OXqm
    Leave group <email obscured>?Subject=Unsubscribe




    *** Only open attachments or links from trusted senders. Report phishing to
<email obscured> ***

=====================================================================

     Please note that this e-mail and any files transmitted from
     Memorial Sloan Kettering Cancer Center may be privileged, confidential,
     and protected from disclosure under applicable law. If the reader of
     this message is not the intended recipient, or an employee or agent
     responsible for delivering this message to the intended recipient,
     you are hereby notified that any reading, dissemination, distribution,
     copying, or other use of this communication or any of its attachments
     is strictly prohibited.  If you have received this communication in
     error, please notify the sender immediately by replying to this message
     and deleting this message, any attachments, and all copies and backups
     from your computer.